These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22943641)

  • 21. Variability in CYP2C9 allele frequency: a pilot study of its predicted impact on warfarin response among healthy South and North Indians.
    Nahar R; Deb R; Saxena R; Puri RD; Verma IC
    Pharmacol Rep; 2013; 65(1):187-94. PubMed ID: 23563037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extremely low warfarin dose in patients with genotypes of CYP2C9*3/*3 and VKORC1-1639A/A.
    Gao L; He L; Luo J; Xu B; Yang J; Zhang YX; Yang T; Li K; Tian JW; Wang HJ; Zhao YS; Lu CY; Zhang WZ; Yin T
    Chin Med J (Engl); 2011 Sep; 124(17):2767-70. PubMed ID: 22040439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.
    Obayashi K; Nakamura K; Kawana J; Ogata H; Hanada K; Kurabayashi M; Hasegawa A; Yamamoto K; Horiuchi R
    Clin Pharmacol Ther; 2006 Aug; 80(2):169-78. PubMed ID: 16890578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High resolution melting method to detect single nucleotide polymorphism of VKORC1 and CYP2C9.
    Chen C; Li S; Lu X; Tan B; Huang C; Qin L
    Int J Clin Exp Pathol; 2014; 7(5):2558-64. PubMed ID: 24966969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CYP2C9 and VKORC1 polymorphisms are differently distributed in the Brazilian population according to self-declared ethnicity or genetic ancestry.
    Soares RA; Santos PC; Machado-Coelho GL; do Nascimento RM; Mill JG; Krieger JE; Pereira AC
    Genet Test Mol Biomarkers; 2012 Aug; 16(8):957-63. PubMed ID: 22808915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical significance of combined CYP2C9 and VKORC1 genotypes in Japanese patients requiring warfarin.
    Miyagata Y; Nakai K; Sugiyama Y
    Int Heart J; 2011; 52(1):44-9. PubMed ID: 21321468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cross-Validation of High-Resolution Melting Analysis-Based Genotyping Platform.
    Langaee T; Stauffer L; Galloway C; Solayman MH; Cavallari L
    Genet Test Mol Biomarkers; 2017 Apr; 21(4):259-264. PubMed ID: 28384046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic and pharmacodynamic variation associated with VKORC1 and CYP2C9 polymorphisms in Thai patients taking warfarin.
    Sangviroon A; Panomvana D; Tassaneeyakul W; Namchaisiri J
    Drug Metab Pharmacokinet; 2010; 25(6):531-8. PubMed ID: 20930419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of CYP2C9 and VKORC1 alleles in the Argentine population and implications for prescribing dosages of anticoagulants.
    Scibona P; Redal MA; Garfi LG; Arbelbide J; Argibay PF; Belloso WH
    Genet Mol Res; 2012 Jan; 11(1):70-6. PubMed ID: 22290467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenetics of coumarin dosing: prevalence of CYP2C9 and VKORC1 polymorphisms in the Lebanese population.
    Djaffar-Jureidini I; Chamseddine N; Keleshian S; Naoufal R; Zahed L; Hakime N
    Genet Test Mol Biomarkers; 2011 Nov; 15(11):827-30. PubMed ID: 21651319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genotyping of CYP2C9 and VKORC1 in the Arabic population of Al-Ahsa, Saudi Arabia.
    Alzahrani AM; Ragia G; Hanieh H; Manolopoulos VG
    Biomed Res Int; 2013; 2013():315980. PubMed ID: 23586031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distribution of CYP2C9 and VKORC1 risk alleles for warfarin sensitivity and resistance in the Israeli population.
    Efrati E; Elkin H; Sprecher E; Krivoy N
    Curr Drug Saf; 2010 Jul; 5(3):190-3. PubMed ID: 20210733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.
    Scott SA; Edelmann L; Kornreich R; Desnick RJ
    Am J Hum Genet; 2008 Feb; 82(2):495-500. PubMed ID: 18252229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response.
    Molden E; Okkenhaug C; Ekker Solberg E
    Eur J Clin Pharmacol; 2010 May; 66(5):525-30. PubMed ID: 20354686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of CYP2C9 and VKORC1 genetic polymorphisms on mean daily maintenance dose of acenocoumarol in South Indian patients.
    Krishna Kumar D; Madhan S; Balachander J; Sai Chandran BV; Thamijarassy B; Adithan C
    Thromb Res; 2013 Apr; 131(4):363-7. PubMed ID: 23473641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenetics of acenocoumarol in patients with extreme dose requirements.
    Pérez-Andreu V; Roldán V; López-Fernández MF; Antón AI; Alberca I; Corral J; Montes R; García-Barberá N; Ferrando F; Vicente V; González-Conejero R
    J Thromb Haemost; 2010 May; 8(5):1012-7. PubMed ID: 20149073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of CYP2C9 and vitamin k oxide reductase complex (VKORC)1 polymorphisms on time to determine the warfarin maintenance dose.
    Aomori T; Obayashi K; Fujita Y; Araki T; Nakamura K; Nakamura T; Kurabayashi M; Yamamoto K
    Pharmazie; 2011 Mar; 66(3):222-5. PubMed ID: 21553655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The combined effects of clinical factors and CYP2C9 and VKORC1 gene polymorphisms on initiating warfarin treatment in patients after cardiac valve surgery.
    Tatarūnas V; Lesauskaite V; Veikutiene A; Grybauskas P; Jakuska P; Benetis R
    J Heart Valve Dis; 2012 Sep; 21(5):628-35. PubMed ID: 23167228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.
    Borgiani P; Ciccacci C; Forte V; Romano S; Federici G; Novelli G
    Pharmacogenomics; 2007 Nov; 8(11):1545-50. PubMed ID: 18034619
    [TBL] [Abstract][Full Text] [Related]  

  • 40. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.
    Schalekamp T; Brassé BP; Roijers JF; Chahid Y; van Geest-Daalderop JH; de Vries-Goldschmeding H; van Wijk EM; Egberts AC; de Boer A
    Clin Pharmacol Ther; 2006 Jul; 80(1):13-22. PubMed ID: 16815313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.